Indivior Pharmaceuticals, Inc. Selling, General and Administrative Expense
Indivior Pharmaceuticals, Inc. (INDV) reported Selling, General and Administrative Expense of $122.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $122.00M, a 22.78% decline year-over-year.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $124.00M, a 6.77% decline year-over-year.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $189.00M, a 8.00% increase year-over-year.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $155.00M, a 9.15% increase year-over-year.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2025 was $634.00M, a 3.59% increase from fiscal 2024.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2024 was $612.00M, a 8.32% increase from fiscal 2023.
- Indivior Pharmaceuticals, Inc. selling, general and administrative expense for fiscal 2023 was $565.00M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $122.00M 10-Q · filed 2026-08-03 | $245.00M 10-Q · filed 2026-08-03 | $435.00M derived: sum of 3 quarters · filed 2026-08-03 | $590.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2026-03-31 | $124.00M 10-Q · filed 2026-04-30 | $313.00M derived: sum of 2 quarters · filed 2026-04-30 | $468.00M derived: sum of 3 quarters · filed 2026-04-30 | $626.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-12-31 | $189.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $344.00M derived: sum of 2 quarters · filed 2026-02-26 | $502.00M derived: sum of 3 quarters · filed 2026-08-03 | $634.00M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $155.00M 10-Q · filed 2025-10-30 | $313.00M derived: sum of 2 quarters · filed 2026-08-03 | $445.00M 10-Q · filed 2025-10-30 | $621.00M derived: sum of 4 quarters · filed 2026-08-03 | |||
| 2025-06-30 | $158.00M 10-Q · filed 2026-08-03 | $291.00M 10-Q · filed 2026-08-03 | $290.00M 10-Q · filed 2025-07-31 | $466.00M derived: sum of 3 quarters · filed 2026-08-03 | $608.00M derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-03-31 | $133.00M 10-Q · filed 2026-04-30 | $132.00M 10-Q · filed 2025-05-01 | $308.00M derived: sum of 2 quarters · filed 2026-04-30 | $450.00M derived: sum of 3 quarters · filed 2026-04-30 | $602.00M derived: sum of 4 quarters · filed 2026-04-30 | ||
| 2024-12-31 | $175.00M 10-K · filed 2026-02-26 | $317.00M derived: sum of 2 quarters · filed 2026-02-26 | $469.00M derived: sum of 3 quarters · filed 2026-02-26 | $612.00M 10-K · filed 2026-02-26 | $618.00M 10-K · filed 2025-03-03 | ||
| 2024-09-30 | $142.00M 10-K · filed 2026-02-26 | $294.00M derived: sum of 2 quarters · filed 2026-02-26 | $437.00M 10-Q · filed 2025-10-30 | ||||
| 2024-06-30 | $152.00M 10-K · filed 2026-02-26 | $295.00M 10-Q · filed 2025-07-31 | |||||
| 2024-03-31 | $143.00M 10-K · filed 2026-02-26 | ||||||
| 2023-12-31 | $565.00M 10-K · filed 2026-02-26 | $569.00M 10-K · filed 2025-03-03 | |||||
| 2022-12-31 | $466.00M 10-Q · filed 2025-10-30 | $469.00M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |